Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03781986 | APG-115 in Salivary Gland Cancer Trial | PHASE2 | ACTIVE NOT_RECRUITING | 41 | — | — | Oct 28, 2019 | Jan 1, 2027 | Mar 3, 2026 | 3 | United States, United States +1 |
| Name | Type | Description |
|---|---|---|
| APG-115 | DRUG | APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days. |
| Carboplatin | DRUG | Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days. |